Literature DB >> 2152849

Histopathologic features of hepatocellular carcinoma in Zaire.

L O Kashala1, B Conne, M M Kalengayi, Y Kapanci, P C Frei, P H Lambert.   

Abstract

The pathology of hepatocellular carcinoma (HCC) was studied based on 223 Zairian HCC cases registered from 1966 to 1985. The observations included the following: (1) hepatitis B surface antigen (HBsAg) status, (2) histologic types, (3) degree of cellular differentiation, and (4) frequency and types of the accompanying cirrhosis. Serum HBsAg was positive in 56.7% of HCC patients and 5.7% of controls (P less than 0.001). Immunohistochemical localization of HBsAg was positive in 53.3% in normal hepatocytes and in 10% in neoplastic cells. Morphologically, mixed type HCC (48.4%), trabecular (31.4%), and compact variants (13.5%) were predominant. Clear cell and pseudoglandular variants were rare (less than 1%). The majority of tumors (83%) were poorly differentiated HCC (Grades: 2-3, 3, 3-4, and 4). Well-differentiated HCC were extremely rare (0.5%). Fifty percent of HCC arose in a cirrhotic liver, predominantly of the macronodular (67.4%) inactive (55%) type. The micronodular cirrhosis was very uncommon (1.1%). These findings clearly show the excess of poorly differentiated HCC in African patients and suggest a possible link between the morphologic features of HCC in Africa and its extraordinary fast-running course.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2152849     DOI: 10.1002/1097-0142(19900101)65:1<130::aid-cncr2820650126>3.0.co;2-s

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

Review 1.  Paediatric oncology in developing countries.

Authors:  G Prindull
Journal:  Eur J Pediatr       Date:  1991-08       Impact factor: 3.183

2.  Primary clear cell carcinoma in the liver: CT and MRI findings.

Authors:  Qing-Yu Liu; Hai-Gang Li; Ming Gao; Xiao-Feng Lin; Yong Li; Jian-Yu Chen
Journal:  World J Gastroenterol       Date:  2011-02-21       Impact factor: 5.742

3.  A case of primary clear cell hepatocellular carcinoma in a non-cirrhotic liver: an immunohistochemical and ultrastructural study.

Authors:  Erica Fan Clayton; Emma Elizabeth Furth; Amy Ziober; Theodore Xu; Yuan Yao; Pil Gyu Hwang; Zhanyong Bing
Journal:  Rare Tumors       Date:  2012-05-17

4.  Hepatocellular carcinoma with foamy histiocyte-like appearance: a deceptively clear cell carcinoma appearing variant.

Authors:  Takuji Noro; Naoto Gotohda; Motohiro Kojima; Masaru Konishi; Toshio Nakaghori; Shinichiro Takahashi; Takayuki Hasebe; Taira Kinoshita
Journal:  Case Rep Gastroenterol       Date:  2010-08-03

5.  Dichotomous associations of liver pathology with hepatocellular carcinoma morphology in Middle Africa: the situation in Cameroon.

Authors:  Marie Atsama Amougou; Paul Jean Adrien Atangana; Alice Ghislaine Ndoumba Afouba; Paul Fewou Moundipa; Pascal Pineau; Richard Njouom
Journal:  BMC Res Notes       Date:  2018-07-09

6.  Octreotide and celecoxib synergistically encapsulate VX2 hepatic allografts following transcatheter arterial embolisation.

Authors:  Huan Tong; Xiao Li; Chun-LE Zhang; Jin-Hang Gao; Shi-Lei Wen; Zhi-Yin Huang; Cheng-Wei Tang
Journal:  Exp Ther Med       Date:  2013-01-16       Impact factor: 2.447

7.  Long-term survival and prognosis for primary clear cell carcinoma of the liver after hepatectomy.

Authors:  Zu-Shun Chen; Shao-Liang Zhu; Lu-Nan Qi; Le-Qun Li
Journal:  Onco Targets Ther       Date:  2016-07-06       Impact factor: 4.147

8.  The role of T2*-weighted gradient echo in the diagnosis of tumefactive intrahepatic extramedullary hematopoiesis in myelodysplastic syndrome and diffuse hepatic iron overload: a case report and review of the literature.

Authors:  Abel A Belay; Andrew M Bellizzi; Alan H Stolpen
Journal:  J Med Case Rep       Date:  2018-01-15

9.  Simultaneous renal clear cell carcinoma and primary clear cell carcinoma of the liver: A case report.

Authors:  Hua Jiang; Shanchao Zhao; Ganhong Li
Journal:  Medicine (Baltimore)       Date:  2020-11-20       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.